Table 1.
Main general characteristics according to ACEi-based or ARB-based triple therapy
| All study population (n = 520) | Patients taking ACEi-based triple therapy (n = 189) | Patients taking ARB-based triple therapy (n = 331) | p* | |
|---|---|---|---|---|
| Age (years) | 62.7 ± 12.2 | 62.4 ± 11.8 | 62.8 ± 12.3 | 0.728 |
| Sex (male) | 61.7% | 64.6% | 60.1% | 0.318 |
| BMI (kg/m2) | 28.4 ± 4.4 | 28.2 ± 4.3 | 28.6 ± 4.4 | 0.329 |
| Smoking habit | 51.3% | 50.8% | 51.7% | 0.849 |
| T2DM | 25.4% | 29.9% | 22.8% | 0.073 |
| eGFR (ml/min/1.73 m2) | 77.1 ± 22.8 | 77.7 ± 22.3 | 76.8 ± 23.1 | 0.660 |
| Number of antihypertensive pills | ||||
| 1 | 8.1% | 22.2% | 0.0% | |
| 2 | 87.3% | 77.2% | 93.1% | < 0.001 |
| 3 | 4.6% | 0.5% | 6.9% | |
| ATI | 5.49 ± 0.37 | 5.44 ± 0.40 | 5.52 ± 0.36 | 0.017 |
| Use of concomitant medications | 61.3% | 58.5% | 62.7% | 0.429 |
*Comparison between patients taking ACEi-based triple therapy vs patients taking ARB-based triple therapy
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, T2DM type 2 diabetes mellitus, eGFR estimated glomerular filtration rate, ATI antihypertensive treatment intensity